FLT3 and acute myeloid leukemia: Patients with relapsed or refractory (R/R) AML in Japan are currently treated with chemotherapy, gemtuzumab ozogamicin, or FLT3 inhibitors [5], although none of these therapies provide a satisfactory therapeutic effect [1].